The U.S. Supreme Court has rejected an appeal that sought to revive a class-action lawsuit against Eli Lilly over its antipsychotic drug Zyprexa, according to a Wall Street Journal report.
Insurers claim they overpaid for Zyprexa due to misrepresentations of the drug's safety and efficacy since Lilly allegedly promoted the drug for uses not approved by the Food and Drug Administration. Lilly agreed to pay $1.42 billion in 2009 after pleading guilty to a criminal charge in a settlement with federal prosecutors who accused the company of illegally marketing Zyprexa, according to the report.
Without comment, the Supreme Court refused to disturb the 2nd Circuit of Appeals' ruling from last year, which found the plaintiffs' claims too attenuated because there wasn't a direct link between the prices they paid for the blockbuster drug and Lilly's alleged marketing misrepresentations.
Read the Wall Street Journal report on Eli Lilly.
Related Articles on Pharmaceutical Fraud:
Johnson & Johnson to Pay South Carolina $327M for Deceptive Drug Marketing
Michigan Accuses McKesson of Inflating Drug Prices, Overbilling Medicaid
UCB Pleads Guilty to Off-Label Marketing of Epilepsy Drug; Will Pay $34M
Insurers claim they overpaid for Zyprexa due to misrepresentations of the drug's safety and efficacy since Lilly allegedly promoted the drug for uses not approved by the Food and Drug Administration. Lilly agreed to pay $1.42 billion in 2009 after pleading guilty to a criminal charge in a settlement with federal prosecutors who accused the company of illegally marketing Zyprexa, according to the report.
Without comment, the Supreme Court refused to disturb the 2nd Circuit of Appeals' ruling from last year, which found the plaintiffs' claims too attenuated because there wasn't a direct link between the prices they paid for the blockbuster drug and Lilly's alleged marketing misrepresentations.
Read the Wall Street Journal report on Eli Lilly.
Related Articles on Pharmaceutical Fraud:
Johnson & Johnson to Pay South Carolina $327M for Deceptive Drug Marketing
Michigan Accuses McKesson of Inflating Drug Prices, Overbilling Medicaid
UCB Pleads Guilty to Off-Label Marketing of Epilepsy Drug; Will Pay $34M